- Home
- BLRX vs BNC Comparison
BLRX vs BNC Comparison
Compare BLRX & BNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- BNC
- Stock Information
- Founded
- BLRX 2003
- BNC N/A
- Country
- BLRX Israel
- BNC United States
- Employees
- BLRX N/A
- BNC N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- BNC Industrial Machinery/Components
- Sector
- BLRX Health Care
- BNC Industrials
- Exchange
- BLRX Nasdaq
- BNC Nasdaq
- Market Cap
- BLRX 17.0M
- BNC 13.7M
- IPO Year
- BLRX 2011
- BNC N/A
- Fundamental
- Price
- BLRX $3.67
- BNC $20.50
- Analyst Decision
- BLRX Strong Buy
- BNC
- Analyst Count
- BLRX 2
- BNC 0
- Target Price
- BLRX $19.00
- BNC N/A
- AVG Volume (30 Days)
- BLRX 32.7K
- BNC 363.0K
- Earning Date
- BLRX 08-14-2025
- BNC 09-19-2025
- Dividend Yield
- BLRX N/A
- BNC N/A
- EPS Growth
- BLRX N/A
- BNC N/A
- EPS
- BLRX N/A
- BNC N/A
- Revenue
- BLRX $17,251,000.00
- BNC $3,478,254.00
- Revenue This Year
- BLRX N/A
- BNC N/A
- Revenue Next Year
- BLRX N/A
- BNC N/A
- P/E Ratio
- BLRX N/A
- BNC N/A
- Revenue Growth
- BLRX 1.19
- BNC 10.08
- 52 Week Low
- BLRX $2.30
- BNC $5.60
- 52 Week High
- BLRX $26.80
- BNC $82.88
- Technical
- Relative Strength Index (RSI)
- BLRX 44.89
- BNC N/A
- Support Level
- BLRX $3.42
- BNC N/A
- Resistance Level
- BLRX $3.79
- BNC N/A
- Average True Range (ATR)
- BLRX 0.25
- BNC 0.00
- MACD
- BLRX 0.02
- BNC 0.00
- Stochastic Oscillator
- BLRX 47.17
- BNC 0.00
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.